Your browser doesn't support javascript.
loading
The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis.
Dong, Yuanmei; Ye, Sisi; Li, Huizi; Li, Juan; Liu, Rongrui; Zhu, Yanyun.
Afiliação
  • Dong Y; Department of Medical Oncology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.
  • Ye S; Department of Medical Oncology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.
  • Li H; Department of Nutrition, PLA Rocket Force Characteristic Medical Center, Beijing 100088, China.
  • Li J; Department of Medical Oncology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.
  • Liu R; Department of Medical Oncology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.
  • Zhu Y; Department of Medical Oncology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.
J Pers Med ; 14(2)2024 Jan 23.
Article em En | MEDLINE | ID: mdl-38392565
ABSTRACT

BACKGROUND:

Colorectal cancer (CRC) is the leading cause of cancer deaths, and treatment, especially in the metastatic stage, is challenging. Immune checkpoint inhibitors (ICIs) have revolutionized CRC treatment, but response varies, emphasizing the need for effective biomarkers. This study explores SPEN mutations as potential biomarkers.

METHODS:

Using data from the Memorial Sloan Kettering Cancer Center (MSKCC) and The Cancer Genome Atlas (TCGA)-Colorectal Cancer, this research applied bioinformatics tools and statistical analysis to SPEN (Split Ends) mutant and wild-type CRC patients treated with ICIs. Focus areas included mutation rates, immune cell infiltration, and DNA damage response pathways.

RESULTS:

The SPEN mutation rate was found to be 13.8% (15/109 patients) in the MSKCC cohort and 6.65% (35/526 patients) in the TCGA cohort. Our findings indicate that CRC patients with SPEN mutations had a longer median overall survival (OS) than the wild-type group. These patients also had higher tumor mutational burden (TMB), microsatellite instability (MSI) scores, and programmed death-ligand 1 (PD-L1) expression. SPEN mutants also exhibited increased DNA damage response (DDR) pathway mutations and a greater presence of activated immune cells, like M1 macrophages and CD8+ T cells, while wild-type patients had more resting/suppressive immune cells. Furthermore, distinct mutation patterns, notably with TP53, indicated a unique molecular subtype in SPEN-mutated CRC.

CONCLUSIONS:

We conclude that SPEN mutations might improve ICI efficacy in CRC due to increased immunogenicity and an inflammatory tumor microenvironment. SPEN mutations could be predictive biomarkers for ICI responsiveness, underscoring their value in personalized therapy and highlighting the importance of genomic data in clinical decisions. This research lays the groundwork for future precision oncology studies.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article